Back to all webinars
Expert review of ASH 2023: Actionable insights in CLL and indolent lymphomas
Stephan Stilgenbauer, Meletios Dimopoulos, and Stefano Luminari look back on ASH, highlighting developments with BTK inhibitor-based therapies in CLL and immunotherapies in FL.
Speakers
Highlights in CLL presented at ASH 2023
Fast-forward to:
SEQUOIA study: Zanubrutinib vs. BR in TN CLL/SLL
65ce0cd5e80cae1e5f33b5b7
ELEVATE TN 6-year follow-up: Acalabrutinib ± obinutuzumab vs. obinutuzumab + Clb in TN CLL
65ce0d0f2ff11c1e67ebc13e
FLAIR study: MRD-directed ibrutinib-venetoclax vs. FCR in TN CLL
65ce0d2e6b78491e6005bcf2
GAIA/CLL13 and CAPTIVATE studies: Fixed-duration targeted combinations in TN CLL
65ce0d5c6c5c501e59051597
ALPINE study: Zanubrutinib vs. ibrutinib in R/R CLL/SLL
65ce0d7fe80cae1e5f33b5c2
Highlights in indolent lymphomas presented at ASH 2023
Fast-forward to:
EPCORE NHL-I study: Epcoritamab subcutaneous monotherapy in R/R follicular lymphoma
65ce11f6e80cae1e5f33b5f0
TRANSCEND FL study: Liso-cel in 2L high-risk R/R follicular lymphoma
65ce12a12ff11c1e67ebc17c
DESCAR-T registry: Real-world outcomes with CAR-T therapy in R/R follicular lymphoma
65ce12fa2ff11c1e67ebc184
Subcutaneous mosenutuzumab in TN follicular lymphoma
65ce138de80cae1e5f33b60b
Audience question: In follicular lymphoma, are there data for patients treated with CAR-T therapy after relapse on a bispecific monoclonal antibody, and vice versa?
65ce13ce6b78491e6005bd3b
Summary
No entries